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Abstract
Background
Revascularization of saphenous vein grafts (SVGs) is challenging and debated for the last few decades. The
percutaneous revascularization of SVGs was reported to have poorer long-term outcomes than native
coronary artery revascularization.
Purpose
We aim to study the peri-procedural complications and long-term outcomes of the percutaneous
revascularization of SVGs in a low-middle-income country.
Methods
In this retrospective study, we included 110 patients who underwent percutaneous revascularization from
January 2011 to March 2020 and followed them retrospectively for long-term outcomes and major adverse
cardiovascular events.
Results
The mean age was 71 ±9, and 81% were male. The most common reason for the presentation was non-ST
segment elevation myocardial infarction (NSTEMI) (46%). The mean follow-up period of the study was 48±27
months. The most common comorbidity was hypertension (86%). A drug-eluting stent (80%) was placed in
most of the patients, followed by a bare-metal stent (BMS) (14%) and percutaneous balloon angioplasty
(POBA) (6%). We did not find any significant difference in major adverse cardiac events (MACE) (P=0.48),
target vessel revascularization (TVR) (p=0.69), and target lesion revascularization (TLR) (p=0.54) with drug-
eluting stent (DES) as compared to either BMS or POBA. The mean period from coronary artery bypass
grafting (CABG) to SVG percutaneous coronary intervention (PCI) was 15± 5.5 years. Multivariate Cox
regression analysis showed that an acute coronary syndrome (ACS) event, stroke, and female sex were
independently associated with MACE.
Conclusion
The long-term outcomes of SVG PCI are not affected by the types of stents. Female gender, ACS, and stroke
are the independent predictors of MACE after SVG PCI, and statin therapy has a positive impact on the long-
term outcomes of SVG PCI.
Categories: Cardiac/Thoracic/Vascular Surgery
Keywords: percutaneous intervention, low to middle income countries, saphenous vein graft
Introduction
Cardiovascular diseases are the leading cause of death worldwide, and coronary artery disease accounts for
more than 40% of cardiovascular deaths [1]. Coronary artery bypass grafting (CABG) is a recommended
revascularization procedure for complex coronary artery disease associated with better long-term outcomes,
especially in patients with left main or multivessel coronary artery disease [2].
Although CABGs overall are reported to have a lower rate of repeat revascularization than percutaneous
coronary intervention (PCI), saphenous vein grafts (SVGs) are prone to early atherosclerosis and
degeneration, leading to graft occlusion [3] As high as 20% of the SVGs develop obstructive lesions and
occluded in the first 18 months due to accelerated intimal hyperplasia [4-5]. At 10 years, more than 50% of
the SVGs were found to be occluded [6-7].
1 1 1 2 3
 
Open Access Original
Article  DOI: 10.7759/cureus.11496
How to cite this article
Adnan G, Ahmed I, Tai J, et al. (November 16, 2020) Long-Term Clinical Outcomes of Percutaneous Coronary Intervention in Saphenous Vein
Grafts in a Low to Middle-Income Country. Cureus 12(11): e11496. DOI 10.7759/cureus.11496
The revascularization of SVGs is challenging and has been a matter of debate for the last few decades. A re-
do coronary bypass graft is not recommended in the setting of a patent internal mammary graft to the left
anterior descending artery, as it is associated with high perioperative complications [8]. The percutaneous
revascularization of SVGs was reported to have a lower success rate and poor long-term outcomes as
compared to native coronary artery percutaneous revascularization [9-10].
SVG intervention is not similar to that of native coronary artery percutaneous coronary intervention (PCI).
Many factors described in the literature make SVG intervention challenging. These may include the
arterialization of the vein graft due to high pressure, leading to intimal hyperplasia and atherosclerosis, a
thin cap of atherosclerotic plaque, which makes it vulnerable for distal embolization intervention, and a
large thrombus burden, especially in acute occlusion [11-12]. All these factors, along with the release of
neurohumoral factors, lead to no-reflow, which increases the risk of peri-procedure myocardial infarction
and affects short and long-term outcomes [13].
As the prevalence of coronary artery disease increases in low-middle-income countries, it is essential to
generate local evidence to increase the effectiveness of coronary artery disease treatment strategies. We aim
to study the peri-procedural complications, as well as the long and short-term outcomes of SVG PCI in a
low-middle-income country.
Materials And Methods
We conducted a retrospective study at a major tertiary care hospital in Karachi. We enrolled in a cohort of
patients from the last 10 years, i.e., 2010-2019, aged >18 years old who underwent PCI of SVG. Data were
collected by reviewing the medical records of patients who fulfill inclusion criteria 1) >18 years of age, 2) PCI
of the saphenous vein graft with either balloon angioplasty or stent (drug-eluting stent (DES) and bare-
metal stent (BMS)). We excluded the patients who underwent PCI of native arteries.
We assessed demographic parameters, comorbidities at presentation, family history, cardiovascular risk
factors, medications, previous PCI, and ejection fraction from the database. Procedural features were also
recorded, i.e., native vessel disease, graft vessel disease, PCI of graft, type of procedure, reference vessel,
number of stents, stent length, stent diameter, target vessel revascularization, guide catheter, guidewire,
aspiration, thrombus, pre-dilation, post-dilation, and percentage of stenosis. We also followed for post-
procedure events.
Operational definition
Event: Major adverse cardiac event (MACE) defined as cardiac death, myocardial infarction, stroke, and
revascularization (including both target vessel revascularization and target lesion revascularization).
Target vessel revascularization (TVR): Defined as repeat percutaneous intervention of previously stented
SVG graft.
Target lesion revascularization (TLR): Defined as repeat percutaneous intervention within 5 mm proximal or
distal of previously stented SVG graft.
Statistical analysis
Data were analyzed using statistical software STATA (version 14.2; StataCorp, College Station, TX). In the
descriptive analysis, mean and standard deviation were calculated for quantitative variables and proportions
for qualitative variables, including the dependent variable. We did a univariate analysis with Cox
proportional hazard regression in which association between independent variables was observed with the
outcome. The final multivariable Cox regression model was developed using a stepwise approach through
model building, considering p-value <0.05 statistically significant. After that, the global test for the
proportional hazard assumption was performed. Acute coronary syndrome (ACS) event, stroke, and sex
remained in the parsimonious model. Survival analysis was demonstrated by Kaplan Meier curves and
compared with the log-rank test.
Results
Between January 2011 and March 2020, a bypass graft angiogram was performed in 650 patients, out of
which 111 patients with PCI of SVG were included. The mean age was 71 ±9, and 81% were male. The most
common reason for the presentation was non-ST segment elevation myocardial infarction (NSTEMI) (46%).
The mean follow-up period of the study was 48±27 months. The baseline characteristics of the patient are
shown in Table 1. The most common comorbidity was hypertension (86%), followed by diabetes (66%),
dyslipidemia (24%), stroke (3.60%), and chronic kidney disease (CKD) (15%).
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Age 71 ±9
Gender (male) 90(81%)
Hypertension 96(86%)
Diabetes 73 (66%)
Chronic kidney disease 17(15%)
Dyslipidemia 27(24%)
Stroke 4(3.6%)
Left ventricle ejection fraction<45% 57(51%)
Previous PCI 23(21%)
NSTEMI 51(46%)
STEMI 11(10%)
Unstable angina 23(21%)
Stable angina 26(23%)
Beta-blocker 97(87%)
Nitrate 27(24%)
ACE inhibitors 35(31%)
Calcium channel blocker 32(28%)
Statin 109(98%)
Angiotensin receptor blocker 24(21%)
TABLE 1: Baseline clinical characteristics of patients
PCI: percutaneous coronary intervention; NSTEMI: non-ST segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial
infarction; ACE: angiotensin-converting enzyme
The patients' angiographic and procedural characteristics of SVG PCI are shown in Table 2.
Native LM Disease 38(34%)
Native LAD disease 108(97%)
Native Ramus disease 11(10%)
Native LCX disease 104(94%)
Native RCA disease 106(96%)
LIMA-LAD disease 14(13%)
SVG-LAD disease 15(14%)
SVG-Diagonal disease 29(26%)
SVG-Ramus disease 8(7%)
SVG-OM disease 74(67%)
SVG-RCA disease 68(61%)
Thrombus 21(19%)
Aspiration 24(22%)
Stenosis percentage>90% 84(75%)
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Guide catheter
Left coronary bypass catheter 52(47%)
Judkins right 28(25%)
Amplatz left 5(4%)
Multipurpose catheter 25(23%)
Internal mammary catheter 1(1 %)
Guidewire
Balance middleweight (BMW) wire 85(77%)
Run-through 11(10%)
Whisper 3(2.70%)
Cougar XT 3(3%)
Miracle 2(2%)
Fielder FC 1(1%)
Sion 6(5%)
Dilation
Pre-dilation 59(53%)
Post-dilation 75(67%)
Maximum post-dilation 18±4.6
Stent size
Stent diameter 3.23±0.5
Stent length 22.3±9
Stent number
1 76(68%)
2 23(21%)
3 6(5%)
Stent type
Drug-eluting stent (DES) 89(80%)
Bare metal stent (BMS) 15(14%)
Percutaneous balloon angioplasty (POBA) 7(6%)
TABLE 2: Patients' procedural characteristics
LM: left main; LAD: left anterior descending artery; LCX: left circumflex artery; RCA: right coronary artery; LIMA: left internal mammary artery;
SVG: saphenous vein graft; OM: obtuse marginal artery
Most patients in our study who had SVG PCI were also found to have significant (>50% for left main, >70%
for other vessels) disease in native vessels. The most common disease vessels were SVG to OM and SVG to
RCA grafts. We observed that the most common graft in which PCI was performed was SVG to OM (52%).
However, patients with a critical disease in a left internal mammary artery (LIMA) graft were less as
compared with an SVG graft, yet adverse events significantly occur more in patients with LIMA graft disease.
Multivessel graft PCI was performed in 6% of patients. Most of the grafts engaged with LCB (47%) and BMW
wires (77%) were able to cross the lesion successfully. A drug-eluting stent (80%) was placed in most of the
patients, followed by BMS (14%) and POBA (6%). We did not find any significant difference in MACE, TVR,
and TLR with DES as compared to either BMS or POBA. Nevertheless, the higher the number of stents in a
patient, the more the likelihood of adverse outcomes. The average stent diameter 3.23±0.5, and length were
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22.3±9. Direct stenting was done in 41% of patients. It was observed in patients in whom aspiration
thrombectomy was performed either for large thrombus burden or no re-flow associated with adverse
outcomes. It noted that patients with a high thrombus burden have adverse outcomes.
The mean period from CABG to SVG PCI was 15±5.5 years. However, it is noted that significant adverse
events occur after five years of SVG PCI (p=0.08). The results of the events are shown in Table 3.
MACE 18(16%)
TVR 10(9%)
TLR 5(5%)
Death 9(8%)
Cardiac death 3(3%)
TABLE 3: Incidence of events
TVR: target vessel revascularization; TLR: target lesion revascularization
The incidence of all-cause death was nine (8%), MACE 18 (16%), target vessel revascularization 10 (9%), and
target lesion revascularization 5 (5%). Multivariate Cox regression analysis showed that an ACS event,
stroke, and female sex were independently associated with MACE. Kaplan Meier survival (Figure 1) showed
decreased survival in females, stroke, and acute coronary syndrome (Table 4).
FIGURE 1: Kaplan Meier survival in females and stroke patients
Predictors HR p-value 95% CI
Female sex 3.79 0.02 1.16-12.4
Stroke 9.79 <0.001 2.37-40.4
ACS 36.8 <0.001 7.6-178.2
TABLE 4: Predictors of MACE
ACS: acute coronary syndrome; MACE: major adverse cardiac event
Discussion
It is one of the few studies from low and middle-income countries (LMICs) on the long-term outcomes of
SVG PCI. Even in the contemporary era of advanced intervention techniques and embolic protection devices,
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studies from high-income and upper-middle-income countries have reported high peri-procedural
complications and lower long-term outcomes of SVG PCI. In a meta-analysis by Sidik N et al., the peri-
procedural complications of SVG-PCI were reported as 16%, and MACE was as high as 45% at the 36 months
follow-up [14]. According to the ARRIVE (use of aspirin to reduce the risk of initial vascular events in
patients at moderate risk of cardiovascular disease) study, patients undergoing SVG PCI with drug-eluted
stents had higher two-year mortality, myocardial infarction, and stent thrombosis as compared to those who
had native vessel PCI [15]. In another study by Eid-Lidt et al., SVG PCI was associated with high peri-
procedural complications and lower MACE-free long-term survival [16]. The study reveals that most
participants were males, and our study population was relatively older, with a mean age of more than 70
years. In a study by Redfors, the mean age of the participants undergoing saphenous vein graft PCI was 69.3
years, and 84% were males [17]. Although the male gender is an independent risk factor for coronary artery
disease, females were reported to have poor outcomes after coronary intervention due to some reasons [18].
Ahmed et al. studied more than 1,000 patients with SVG grafts and found that female participants were older
than males with a mean age of 69 years. Female gender was associated with poor outcomes after the
percutaneous intervention [19]. On the other hand, the post-CABG trial showed that the male gender was
inclined to have poor results than the female gender [20]. We found that the female gender was
independently associated with significant MACE.
More than 85% of our study population had hypertension, and two-thirds of them had diabetes mellitus.
Around 74% of the patients in our study presented with an ACS, which itself is an independent predictor of
poor outcomes irrespective of intervention. Redfors et al. reported hypertension and diabetes in 91% and
44% of the study population, respectively, and only 56% of their patients presented with ACS [17]. In a study
from China, 61% of the patients undergoing graft PCI were hypertensive, and 73% of the study population
presented with ACS [21].
The mean time from CABG to the requirement of SCG PCI in our study population was around 15 years as
compared with the other studies [14]. The majority of the patients underwent DES in our study, followed by
BMS and POBA, respectively. Although SVG PCI with DES reported being superior to BMS, in terms of long-
term outcomes, we did not find a statistically significant difference in the long-term outcomes and MACE
among these intervention groups [15,22]. Stent diameter, length of the stent, and pre and post-dilatation
were not found to be associated with MACE in our study population. A study by Leborgne supports direct
stenting as pre-dilation is related to distal embolization of debris and increases peri-procedure myocardial
infarction and increased CK-MB levels [23]. However, a retrospective study did not significantly differ in
patients undergoing direct stenting compared to those who underwent pre-dilation in distal embolic
protection devices [24].
Enormous thrombus burden and aspiration thrombectomy was associated with adverse outcomes. Enormous
thrombus burden, especially in the setting of an ACS, is reported to have poor outcomes in patients
undergoing SVG PCI [25]. Aspiration thrombectomy even during native coronary artery revascularization
increases the risk of distal embolization and stroke [26]. However, embolic protection devices are
recommended during SVG PCI to reduce incidents of distal embolization and no-reflow but those devices
were not used in our study population due to limited availability [27].
Other than the female gender, ACS and stroke were independent predictors of MACE in our study
population. In a pooled analysis of around 4,000 patients, Coolong et al. found that plaque burden large
thrombus and SVG degeneration were the strongest predictors of MACE [28]. An ACS is caused by acute
thrombotic occlusion of the SVG graft, which leads to distal embolization and no-reflow. Brodie BR et al.
reported poor outcomes of SVG PCI in ST-elevation myocardial infarction due to distal embolization and
no-reflow [29].
Our study has some limitations. As this is a retrospective, observational study and patients were not
randomized, which may influence the results. The research was done in a single-center, and the sample size
was small, which may not represent the whole population in our region. We do not have a comparison group,
so it is difficult to establish the association of SVG PCI with mortality. We suggest prospective randomized
studies to predict the long-term outcomes of SVG PCI in our region.
Conclusions
Patients undergoing SVG PCI in our population are relatively older and predominantly male. The long-term
outcomes of SVG PCI are not affected by the type of stents. Female gender, ACS, and stroke are independent
predictors of MACE after SVG PCI.
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